Eintrag weiter verarbeiten
Verfügbar über Online-Ressource

Evolution of hiperreflective points after intravitreal dexamethasone implant injection in patients with macular edema associated with retinal vein occlusion

Gespeichert in:

Bibliographische Detailangaben
Zeitschriftentitel: Acta Ophthalmologica
Personen und Körperschaften: Almenara Michelena, C., Ascaso, F.J., Idoate, A., Caramello, C.M., Sánchez, J.I., Berniolles, J., Cristobal, J.
In: Acta Ophthalmologica, 93, 2015, S255
Format: E-Article
Sprache: Englisch
veröffentlicht:
Wiley
Schlagwörter:
Ophthalmology
General Medicine
Details
Zusammenfassung: <jats:sec><jats:title>Purpose</jats:title><jats:p>To analyse the evolution of macular hyperreflective points (<jats:styled-content style="fixed-case">HRP</jats:styled-content>) detected by spectral‐domain optical coherence tomography (<jats:styled-content style="fixed-case">SD</jats:styled-content>‐<jats:styled-content style="fixed-case">OCT</jats:styled-content>) in eyes with macular edema secondary to retinal vein occlusion (<jats:styled-content style="fixed-case">RVO</jats:styled-content>), following treatment with intravitreal dexamethasone implant (Ozurdex<jats:sup>®</jats:sup>).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Retrospective observational study of 45 consecutive cases of <jats:styled-content style="fixed-case">RVO</jats:styled-content>‐associated macular edema: 13 central <jats:styled-content style="fixed-case">RVO</jats:styled-content> and 32 branch <jats:styled-content style="fixed-case">RVO</jats:styled-content> treated with Ozurdex<jats:sup>®</jats:sup>. The relationship between best corrected visual acuity (<jats:styled-content style="fixed-case">BCVA</jats:styled-content>), central macular thickness (<jats:styled-content style="fixed-case">CMT</jats:styled-content>) and the presence of <jats:styled-content style="fixed-case">HRD</jats:styled-content> in <jats:styled-content style="fixed-case">SD</jats:styled-content>‐<jats:styled-content style="fixed-case">OCT</jats:styled-content> before treatment and two months post‐injection was determined.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p><jats:styled-content style="fixed-case">CMT</jats:styled-content> decreased significantly following treatment (527.7 μm vs 308.3 μm, p &lt; 0.001). Although there was a visual acuity improvement in 18 of the 45 eyes (40%), the mean <jats:styled-content style="fixed-case">BCVA</jats:styled-content> difference was not statistically significant (p = 0.373). Numerous <jats:styled-content style="fixed-case">HRP</jats:styled-content> were detected in 24 patients (53.3%), disappearing in 10 of them (41.7%) after corticosteroid intravitreal therapy.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Disappearance of <jats:styled-content style="fixed-case">HRP</jats:styled-content> after an intravitreal dexamethasone impant would support the hypothesis that <jats:styled-content style="fixed-case">HRP</jats:styled-content> could represent some inflammatory cells.</jats:p></jats:sec>
ISSN: 1755-375X
1755-3768
DOI: 10.1111/j.1755-3768.2015.0712